XM không cung cấp dịch vụ cho cư dân của Mỹ.
G
G

Getinge


Tin tức

Nordic corporate earnings week ahead

DIARY-Nordic corporate earnings week ahead July 12 (Reuters) - Diary of Nordic (OMXS30-SK, OBX-OS, OMXHPI-HE, OMXC20) corporate earnings for the week ahead NORDIC EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 15-Jul-2024 NTS ORK.OL Orkla ASA Q2 2024 Orkla ASA Earnings Release 17-Jul-2024 05:00 NEL.OL Nel ASA Q2 2024 Nel ASA Earnings Release 18-Jul-2024 NTS TEL.OL Telenor ASA Q2 2024 Telenor ASA Earnings Release 18-Jul-2024 NTS PGS.OL^G24 5088687729 PGS ASA Tgs Newco AS Q2 2024
A
B
D
E
E
E
G
K
K
N
O
P
S
S
T
T
V
W
A
A
S
T
Y

Getinge Extends, Elevates Partnership With Universeum

BRIEF-Getinge Extends, Elevates Partnership With Universeum July 5 (Reuters) - Getinge AB GETIb.ST : EXTENDS AND ELEVATES PARTNERSHIP WITH UNIVERSEUM Further company coverage: [GETIb.ST] (Gdansk Newsroom)
G

Hargreaves Lansdown, Segro, Umicore

EUROPE RESEARCH ROUNDUP-Hargreaves Lansdown, Segro, Umicore June 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hargreaves Lansdown, Segro and Umicore, on Wednesday. HIGHLIGHTS * GEA Group AG G1AG.DE : Jefferies raises to buy from hold * Hargreaves Lansdown HRGV.L : Jefferies cuts to hold from buy * Oxford Instruments OXIG.L : Berenberg raises target price to 2,945p from 2,640p * Segro SGRO.L : Jefferies cuts to hold from buy *
A
A
B
B
B
B
B
B
B
D
D
G
G
G
G
G
H
H
I
K
K
L
M
R
S
S
S
U
U
V
A
S

JPM cuts Getinge's PT by 11% in tough market

BUZZ-JPM cuts Getinge's PT by 11% in tough market ** J.P.Morgan cuts PT for "underweight"-rated Getinge GETIb.ST by 11% to SEK 165 on continued inflationary headwinds on costs, quality challenges and uncertain order development in China ** The Swedish medical equipment maker's shares are down 2.4% at 0753 GMT ** JPM says the Surgical Workflows unit
G
J

Adidas AG, Crest Nicholson Holdings, Standard Chartered

EUROPE RESEARCH ROUNDUP-Adidas AG, Crest Nicholson Holdings, Standard Chartered June 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas AG, Crest Nicholson Holdings and Standard Chartered, on Monday. HIGHLIGHTS * Adidas AG ADSGn.DE : JP Morgan raises target price to EUR 250 from EUR 240 * Bellway Plc BWY.L : JP Morgan raises target price to 2,790p from 2,780p * Crest Nicholson Holdings Plc CRST.L : Peel Hunt raises target pr
A
A
B
B
B
C
C
C
E
E
G
H
J
L
O
P
S
S
S
U
A
A
F
U

FDA Identified Getinge's Recall Of Vaporizer Sevoflurane Maquet Filling As Class I Recall

BRIEF-FDA Identified Getinge's Recall Of Vaporizer Sevoflurane Maquet Filling As Class I Recall June 13 (Reuters) - Getinge AB GETIb.ST : FDA:GETINGE RECALLS VAPORIZER SEVOFLURANE MAQUET FILLING FOR RISK OF PATIENT AND HEALTH CARE PROFESSIONAL EXPOSURE TO TOXIC CHEMICAL HYDROGEN FLUORIDE FDA: IDENTIFIED GETINGE'S RECALL OF VAPORIZER SEVOFLURANE MAQ
G

Getinge Granted U.S. FDA 510(K) Clearance For Its Innovative Clinical Decision Support Software Talis +Acg

BRIEF-Getinge Granted U.S. FDA 510(K) Clearance For Its Innovative Clinical Decision Support Software Talis +Acg June 12 (Reuters) - Getinge AB GETIb.ST : GETINGE: GRANTED U.S. FDA 510(K) CLEARANCE FOR ITS INNOVATIVE CLINICAL DECISION SUPPORT SOFTWARE TALIS +ACG Source text for Eikon: [ID:] Further company coverage: [GETIb.ST]
G

Getinge Sees Acute Care Therapies 2024-2028 Net Sales Organic Growth Of 3-5%

BRIEF-Getinge Sees Acute Care Therapies 2024-2028 Net Sales Organic Growth Of 3-5% May 15 (Reuters) - Getinge AB GETIb.ST : GETINGE CEO ON ACUTE CARE THERAPIES UNIT: PROJECTS ORGANIC GROWTH IN NET SALES OF 3-5% IN 2024-2028 GETINGE CEO ON LIFE SCIENCE UNIT: PROJECTS ORGANIC GROWTH IN NET SALES OF 6-10% IN 2024-2028 GETINGE CEO ON SURGICAL WORKFLOWS
G

Getinge heart device quality issues weigh as co issues new outlook target

BUZZ-Getinge heart device quality issues weigh as co issues new outlook target ** Shares in Getinge GETIb.ST fall 8% after the medical equipment maker issues new midterm guidance , but says finances will continue to be negatively impacted by ongoing quality issues with its heart devices until new products are launched ** The company said it targets over 12% growth on average in its adjusted EPS for 2024-2028, compared to its previous target for over 10% growth in EPS for 2022-2025 ** "New mid-te
G
J

Getinge limits sale of heart devices in the US after FDA warning

Getinge limits sale of heart devices in the US after FDA warning May 15 (Reuters) - Sweden's Getinge GETIb.ST will limit sales of some of its heart products in the U.S., the medical equipment maker said late on Tuesday, after recent advice from the U.S. Food and Drug Administration (FDA) to move away from its devices. "We have decided to immediately pause promotional activities of the Cardiohelp System and Cardiosave Intra-Aortic Balloon Pump in the U.S.
G

Getinge Says Financial Target 2024-2028 Is Adjusted EPS Growth Of Above 12% On Average

BRIEF-Getinge Says Financial Target 2024-2028 Is Adjusted EPS Growth Of Above 12% On Average May 14 (Reuters) - Getinge AB GETIb.ST : GETINGE'S FINANCIAL TARGET 2024-2028: ADJUSTED EPS GROWTH OF ABOVE 12% ON AVERAGE FOR 2024, GETINGE REPEATS ITS GUIDANCE OF 2-5% ORGANIC GROWTH IN NET SALES AND 3-5% GROWTH FROM ACQUIRED UNITS DOES NOT PROVIDE ANY AN
G

Medical gear maker Getinge falls after FDA issues safety warning

BUZZ-Medical gear maker Getinge falls after FDA issues safety warning Adds company comment in 3rd bullet, updates shares ** Shares in Getinge GETIb.ST drop about 7% after U.S. FDA issued a warning on the safety of two of the Swedish medical equipment maker's heart devices ** FDA advised healthcare facilities to switch from Getinge's heart devices amid safety concerns ** " We take this very seriously and have an ongoing dialogue with the FDA on how to best address this," says Elin Frostehav, Pres
G
S

STOXX 600 closes at record high on earnings, rate cut optimism

UPDATE 2-STOXX 600 closes at record high on earnings, rate cut optimism For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Rio Tinto considered bid for BHP-target Anglo American -report Green energy production in Italy boosts Enel's Q1 results Medical gear maker Getinge plummets after FDA's safety warning Italy industry output posts unexpected fall in March Updated at 1552 GMT By Ankika Biswas and Johann M Cherian May 10 (Reuters) - Europe
E
G
R
S
S
Z
A
R
E
F
G

New records for STOXX 600, FTSE 100 and DAX; CAC closing in on fresh peak

LIVE MARKETS-New records for STOXX 600, FTSE 100 and DAX; CAC closing in on fresh peak STOXX 600 up 0.6% to new peak DAX and FTSE also at records Wall St futures inch up Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com NEW RECORDS FOR STOXX 600, FTSE 100 AND DAX; CAC CLOSING IN ON FRESH PEAK The pan-European benchmark STOXX 600 .STOXX hit a new intraday record on Friday and is hea
G
E
F
U
G

Medical gear maker Getinge plummets after FDA issues safety warning

BUZZ-Medical gear maker Getinge plummets after FDA issues safety warning ** Shares in Getinge GETIb.ST drop about 8% after U.S. FDA issued a warning on the safety of two of the Swedish medical equipment maker's heart devices ** FDA advised healthcare facilities to switch from Getinge's heart devices amid safety concerns ** Getting did not immediately reply to an emailed request for comment and could not be reached for comment by phone ** Kepler Cheuvreux, via Swedbank Aktiellt, says that while n
G
S

US FDA advises healthcare facilities to switch from Getinge's heart devices

UPDATE 2-US FDA advises healthcare facilities to switch from Getinge's heart devices Adds details in paragraphs 5 & 6, background throughout May 8 (Reuters) - The U.S Food and Drug Administration (FDA) on Wednesday advised healthcare facilities to move away from using Getinge's GETIb.ST heart devices in patients as they faced safety and quality concerns despite a string of recalls.
G

US FDA recommends healthcare providers switch from Getinge's heart devices

US FDA recommends healthcare providers switch from Getinge's heart devices May 8 (Reuters) - The U.S Food and Drug Administration on Wednesday recommended healthcare facilities transition away from using Getinge's GETIb.ST heart devices as they continued to have safety and quality concerns. Reporting by Sriparna Roy in Bengaluru; Editing by Shailes
G

Adriatic Metals, Diageo, GB Group

EUROPE RESEARCH ROUNDUP-Adriatic Metals, Diageo, GB Group April 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adriatic Metals, Diageo and GB Group, on Tuesday. HIGHLIGHTS * Adriatic Metals Plc ADT1.L : Stifel raises target price to 275p from 250p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2400p from 2430p * GB Group Plc GBGP.L : Peel Hunt raises target price to 360p from 340p * H&M HMb.ST : Morgan Stanley raises
A
B
B
D
D
D
G
H
I
L
P
H
G

Getinge Sees FY 2024 Quality-Related Costs At About Half Of Costs In 2023

BRIEF-Getinge Sees FY 2024 Quality-Related Costs At About Half Of Costs In 2023 April 22 (Reuters) - Getinge AB GETIb.ST : GETINGE CEO: HEART BALLOON PUMP BACKLOG GRADUALLY REDUCING, BUT SIGNIFICANT BACKLOG STILL GETINGE CFO: FAIR ASSUMPTION THAT FY 2024 COSTS FOR QUALITY IMPROVEMENTS WOULD BE ABOUT HALF OF QUALITY-RELATED COSTS IN TO 2023 GETINGE
G

Medical gear maker Getinge beats profit expectations, shares jump

UPDATE 3-Medical gear maker Getinge beats profit expectations, shares jump Updates share reaction in paragraph 2, adds CEO, CFO comments in paragraphs 5, 9, 11 By Greta Rosen Fondahn and Elsa Ohlen April 22 (Reuters) - Medical equipment maker Getinge GETIb.ST reported a smaller than expected drop in first-quarter core profit on Monday, as new orders offset the costs of resolving prolonged problems with its product packaging and heart products.
G
J



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.